Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study

Go back to Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
Roche Holding AG Basel American Depositary Shares (AMEX: RHHBY) Delayed: 59.47 +0.36 (0.61%)
Previous Close $59.11    52 Week High $35.13 
Open $58.65    52 Week Low $28.10 
Day High $59.49    P/E N/A 
Day Low $58.41    EPS $0.00 
Volume 508,513